Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

被引：30

作者：

Kaufman, Jonathan L. ^{[1
]}

Usmani, Saad Z. ^{[2
]}

San-Miguel, Jesus ^{[3
]}

Bahlis, Nizar ^{[4
]}

White, Darrell J. ^{[5
,6
]}

Benboubker, Lotfi ^{[7
]}

Cook, Gordon ^{[8
,9
]}

Leiba, Merav ^{[10
]}

Ho, P. Joy

Kim, Kihyun

Takezako, Naoki

Moreau, Philippe ^{[11
]}

Krevvata, Maria ^{[12
]}

Pei, Huiling ^{[13
]}

Ukropec, Jon ^{[14
]}

Renaud, Thomas ^{[15
]}

Trivedi, Sonali ^{[12
]}

Kobos, Rachel ^{[15
]}

Dimopoulos, Meletios A. ^{[16
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[3] Clin Univ Navarra CIMA, IDISNA, CIBERONC, Pamplona, Spain

[4] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[5] Dalhousie Univ, Halifax, NS, Canada

[6] QEII Hlth Sci Ctr, Halifax, NS, Canada

[7] Ctr Hosp Reg Univ CHRU, Serv Hematol & Therapie Cellulaire, Hop Bretonneau, Tours, France

[8] Teaching Hosp NHS Trust, St Jamess Inst Oncol, Leeds, W Yorkshire, England

[9] Univ Leeds, Leeds, W Yorkshire, England

[10] Ben Gurion Univ Negev, Assuta Univ Hosp, Fac Hlth Sci, Beer Sheva, Israel

[11] Univ Hosp Hotel Dieu, Hematol, Nantes, France

[12] Janssen Res & Dev LLC, Spring House, PA USA

[13] Janssen Res & Dev LLC, Titusville, NJ USA

[14] Janssen Global Med Affairs, Horsham, PA USA

[15] Janssen Res & Dev, Raritan, NJ USA

[16] Natl & Kapodistrian Univ Athens, Athens, Greece

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123483

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1866

引用

页数：4

共 50 条

[1] Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
Bahlis, Nizar
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Krevvata, Maria
Chiu, Christopher
Qin, Xiang
Okonkwo, Linda
Trivedi, Sonali
Qi, Ming
San-Miguel, Jesus F.
BLOOD, 2018, 132
[2] Four-year follow-up of the phase 3 POLLUX study of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed or refractory multiple myeloma
Cook, G.
Kaufman, J. L.
Usmani, S. Z.
San-Miguel, J.
Bahlis, N. J.
White, D.
Benboubker, L.
Leiba, M.
Ho, P. J.
Kim, K.
Takezako, N.
Moreau, P.
Krevvata, M.
Pei, H.
Ukropec, J.
Renaud, T.
Trivedi, S.
Kobos, R.
Dimopoulos, M. A.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 20 - 20
[3] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; POLLUX)
Moreau, P.
White, D.
Benboubker, L.
Cook, G.
Leiba, M.
Morton, J.
Ho, P. J.
Kim, K.
Takezako, N.
Trivedi, S.
Wu, K.
Casneuf, T.
Chiu, C.
Schecter, J. M.
Dimopoulos, M. A.
HAEMATOLOGICA, 2018, 103 : 31 - 31
[4] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lofti
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Trivedi, Sonali
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Schecter, Jordan
Moreau, Philippe
BLOOD, 2017, 130
[5] Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
Mateos, Maria-Victoria
Richardson, Paul
Weisel, Katja
Moreau, Philippe
San-Miguel, Jesus
Goldschmidt, Hartmut
Orlowski, Robert
Sonneveld, Pieter
Reece, Donna E.
Suzuki, Kenshi
Bahlis, Nizar
Yoon, Sung-Soo
Spencer, Andrew
Nooka, Ajay
Hungria, Vania
Plesner, Torben
Ben Yehuda, Dina
Pei, Huiling
Mayo, Wendy Garvin
Gai, Xue
Carey, Jodi
Carson, Robin
Dimopoulos, Meletios A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S179 - S180
[6] Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
Bahlis, Nizar J.
Moreau, Philippe
Nahi, Hareth
Plesner, Torben
Goldschmidt, Hartmut
Suzuki, Kenshi
Orlowski, Robert Z.
Rabin, Neil
Leiba, Merav
Oriol, Albert
Chari, Ajai
Miguel, Jesus San
Richardson, Paul G.
Usmani, Saad Zafar
O'Rourke, Lisa Marie
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Qin, Xiang
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Dimopoulos, Meletios A.
San-Miguel, Jesus
Belch, Andrew
White, Darrell
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Sutherland, Heather J.
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, H. Miles
Cochrane, Tara
Oriol, Albert
Bahlis, Nizar J.
Chari, Ajai
O'Rourke, Lisa
Wu, Kaida
Schecter, Jordan M.
Casneuf, Tineke
Chiu, Christopher
Soong, David
Sasser, A. Kate
Khokhar, Nushmia Z.
Avet-Loiseau, Herve
Usmani, Saad Z.
HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
[8] EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED ANALYSIS OF POLLUX
Dimopoulos, M. A.
Moreau, P.
Nahi, H.
Plesner, T.
Goldschmidt, H.
Suzuki, K.
Orlowski, R. Z.
Rabin, N.
Leiba, M.
Oriol, A.
Chari, A.
San-Miguel, J.
Richardson, P. G.
Usmani, S. Z.
O'Rourke, L.
Wu, K.
Casneuf, T.
Chiu, C.
Qin, X.
Bahlis, N. J.
HAEMATOLOGICA, 2017, 102 : 108 - 109
[9] This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX
Dimopoulos, M. A.
Oriol, A.
Nahi, H.
Miguel, J. S.
Bahlis, N. J.
Rabin, N.
Orlowski, R.
Komarnicki, M.
Suzuki, K.
Plesner, T.
Samoilova, O. S.
Yoon, S. S.
Yehuda, D. B.
Richardson, P. G.
Goldschmidt, H.
Reece, D.
Khokhar, N.
O'Rourke, L.
Chiu, C.
Qin, X.
Guckert, M.
Ahmadi, T.
Moreau, P.
HAEMATOLOGICA, 2016, 101 : 342 - 342
[10] Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Mace, Joseph R.
Ahmadi, Tahamtan
Chiu, Christopher
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Qi, Ming
Usmani, Saad Z.
BLOOD, 2018, 132

← 1 2 3 4 5 →